IndiaNapless, IN, United States
IndiaNapless, IN, United States

Eli Lilly and Company is an American global pharmaceutical company with headquarters located in Indianapolis, Indiana, in the United States. The company also has offices in Puerto Rico and 17 other countries. Their products are sold in approximately 125 countries. The company was founded in 1876 by Col. Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War, after whom the company was named.Among other specialties, Lilly was the first company to mass-produce penicillin, the Salk polio vaccine, and insulin, including one of the first pharmaceutical companies to produce human insulin using recombinant DNA. Lilly is also the world's largest manufacturer and distributor of psychiatric medications. In 2009, Eli Lilly pleaded guilty to illegally marketing the drug Zyprexa for off-label uses not approved by the U.S. Food and Drug Administration, particularly the treatment of dementia in the elderly. The company paid a $515 million criminal fine, at the time the largest in history. Wikipedia.


Time filter

Source Type

Patent
Washington University in St. Louis, Eli Lilly and Company | Date: 2017-04-05

A method to treat conditions characterized by formation of amyloid plaques both grophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A.


Patent
Eli Lilly and Company | Date: 2017-01-17

The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.


Patent
Eli Lilly and Company | Date: 2017-01-17

The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.


Patent
Eli Lilly and Company | Date: 2017-01-11

The present invention provides preparation of medicaments for use in treating and methods of treating cancer selected from the group consisting of gastric cancer, HCC, and RCC comprising a C8-H241 Ab, preferably, C8-H241-IgG4, more preferably, emibetuzumab, in combination, as described herein, with an anti-VEGFR2 Ab, preferably, ramucirumab.


Patent
Eli Lilly and Company | Date: 2017-05-17

The invention provides a process for preparing certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I wherein R is hydrogen or methyl, and pharmaceutical compositions thereof.


Patent
Eli Lilly and Company | Date: 2017-01-18

The present invention provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof.


Patent
Eli Lilly and Company | Date: 2017-03-15

The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.


Patent
Eli Lilly and Company | Date: 2017-01-25

The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.


Patent
Eli Lilly and Company | Date: 2017-04-12

An injection device for injecting a medicament includes a housing, a dose setting member (20) movable to set a dose to be injected, and a signal part (7). The signal part rotates from a first rotational position to a second rotational position to increase loading on a spring or spring arm when a dose is set due to rotation of the dose setting member. An internal pressure builds up in the injection device during injection which results in the signal part being captured in the second rotational position between first and second internal parts of the injection device. After the internal pressure dissipates by a sufficient amount during injection, the signal part rotates under the urging of the loaded spring from the second rotational position back to the first rotational position. A portion of the signal part moves into contact with a surface when the signal part reaches the first rotational position to produce tactile or audible feedback indicating that an end of dose condition has been reached.


A TARP 8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is; and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.

Loading Eli Lilly and Company collaborators
Loading Eli Lilly and Company collaborators